close
Add to watchlist
Vanda Pharmaceuticals Inc (VNDA) Healthcare
Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Iloperidone (oral), a compound for the treatment of schizophrenia completed Phase III clinical trial; and Tasimelteon, which completed Phase III clinical trials for transient insomnia and chronic primary insomnia. The company's products also comprise Iloperidone (Injectible) for the treatment of schizophrenia and Tasimelteon for the treatment of depression, which are in the Phase II initiation status. Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.78 |
| Volume | 767452 |
| Volume Avg | 197170 |
| 52 Week High | 8.45 |
| 52 Week Low | 4.33 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.35 |
| EPS change Q/Q | 100% |
| EPS change Q/Q Yr ago | 100% |
| EPS change Q/Q next Q est | 0% |
| EPS change Y/Y | 1000% |
| REV change Q/Q | -3.85% |
| REV change Q/Q Yr ago | -39.52% |
| EPS next Q est | 0.00 |
| EPS next Y est | -0.02 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |